Fluence plays a critical role on the subsequent distribution of chemotherapy and tumor growth delay in murine mesothelioma xenografts pre-treated by photodynamic therapy

Lasers in Surgery and Medicine

Volumn 47, Issue 4, 2015, Pages 323-330

  Wang, Yabo ^a   Wang, Xingyu ^a   Le Bitoux, Marie Aude ^a   Wagnieres, Georges ^a   Vandenbergh, Hubert ^a   Gonzalez, Michel ^a   Ris, Hans Beat ^a   Perentes, Jean Y ^a   Krueger, Thorsten ^a  

^a EPFL   (Switzerland)

Author keywords

drug light conditions; mesothelioma lipoplatin ; photodynamic therapy; tumor response

Indexed keywords

CISPLATIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; LUCIFERASE; VERTEPORFIN; ANTINEOPLASTIC AGENT; DEXTRAN; FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; PHOTOSENSITIZING AGENT; PORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DRUG TRANSPORT; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; MESOTHELIOMA; MESOTHELIOMA CELL LINE; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SKINFOLD; TREATMENT RESPONSE; TUMOR XENOGRAFT; VASCULARIZATION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG SCREENING; MICROSCOPY; NEOADJUVANT THERAPY; NUDE MOUSE; PATHOLOGY; PHOTOCHEMOTHERAPY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DEXTRANS; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; HUMANS; MESOTHELIOMA; MICE, NUDE; MICROSCOPY; NEOADJUVANT THERAPY; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928048803     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.22329     Document Type: Article

References (23)

1. Dolmans DE, Fukumura D, Jain RK,. Photodynamic therapy for cancer. Nat Rev Cancer 2003; 3 (5): 380-387. doi: 10.1038/nrc1071
2. Chen B, Crane C, He C, Gondek D, Agharkar P, Savellano MD, Pogue BW,. Disparity between prostate tumor interior versus peripheral vasculature in response to verteporfin-mediated vascular-targeting therapy. Int J Cancer 2008; 123 (3): 695-701. doi: 10.1002/ijc.23538
3. Chen B, Pogue BW, Zhou X, O'Hara JA, Solban N, Demidenko E, Hasan T,. Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clin Cancer Res 2005; 11 (2 Pt 1): 720-727.
4. Perentes, JY, Wang Y, Wang X, Abdelnour E, Gonzalez M, Decosterd L, Krueger T,. Low-dose vascular photodynamic therapy decreases tumor interstitial fluid pressure, which promotes liposomal doxorubicin distribution in a murine sarcoma metastasis model. Transl Oncol 2014; 7 (3): 393-399. doi: 10.1016/j.tranon.2014.04.010
5. Snyder JW, Greco WR, Bellnier DA, Vaughan L, Henderson BW,. Photodynamic therapy: A means to enhanced drug delivery to tumors. Cancer Res 2003; 63 (23): 8126-8131.
6. Wang Y, Gonzalez M, Cheng C, Haouala A, Krueger T, Peters S, Debefve E,. Photodynamic induced uptake of liposomal doxorubicin to rat lung tumors parallels tumor vascular density. Lasers Surg Med 2012; 44 (4): 318-324.
7. Wang Y, et al. Photodynamic drug delivery enhancement in tumours does not depend on leukocyte-endothelial interaction in a human mesothelioma xenograft model. Eur J Cardiothorac Surg 2012; 42 (2): 348-354.
8. Henderson BW, Gollnick SO, Snyder JW, Busch TM, Kousis PC, Cheney RT, Morgan J,. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 2004; 64 (6): 2120-2126.
9. Debefve E, Cheng C, Schaefer SC, Yan H, Ballini JP, van den Bergh H, Krueger T,. Photodynamic therapy induces selective extravasation of macromolecules: Insights using intravital microscopy. J Photochem Photobiol B 2010; 98 (1): 69-76. doi: 10.1016/j.jphotobiol.2009.11.006
10. Debefve E, Mithieux F, Perentes JY, Wang Y, Cheng C, Schaefer SC, Krueger T,. Leukocyte-endothelial cell interaction is necessary for photodynamic therapy induced vascular permeabilization. Lasers Surg Med 2011; 43 (7): 696-704. doi: 10.1002/lsm.21115
11. Cheng C, Debefve E, Haouala A, Andrejevic-Blant S, Krueger T, Ballini JP, Ris HB,. Photodynamic therapy selectively enhances liposomal doxorubicin uptake in sarcoma tumors to rodent lungs. Lasers Surg Med 2010; 42 (5): 391-399. doi: 10.1002/lsm.20912
12. Cheng C, Haouala A, Krueger T, Mithieux F, Perentes JY, Peters S, Ris HB,. Drug uptake in a rodent sarcoma model after intravenous injection or isolated lung perfusion of free/liposomal doxorubicin. Interact Cardiovasc Thorac Surg 2009; 8 (6): 635-638. doi: 10.1510/icvts.2008.194720
13. Cheng C, Wang Y, Haouala A, Debefve E, Andrejevic Blant S, Krueger T, Perentes JY,. Photodynamic therapy enhances liposomal doxorubicin distribution in tumors during isolated perfusion of rodent lungs. Eur Surg Res 2011; 47 (4): 196-204. doi: 10.1159/000330744
14. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Jain RK,. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012; 7 (6): 383-388. doi: 10.1038/nnano.2012.45
15. Jain RK,. Therapeutic implications of tumor physiology. Curr Opin Oncol 1991; 3 (6): 1105-1108.
16. Jain RK,. The Eugene M. Landis Award Lecture Delivery of molecular and cellular medicine to solid tumors. Microcirculation 1996; 4 (1): 1-23.
17. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK,. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64 (11): 3731-3736. doi: 10.1158/0008-5472.CAN-04-0074
18. Jain RK,. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005; 307 (5706): 58-62. doi: 10.1126/science.1104819
19. Leunig M, Goetz AE, Gamarra F, Zetterer G, Messmer K, Jain RK,. Photodynamic therapy-induced alterations in interstitial fluid pressure, volume and water content of an amelanotic melanoma in the hamster. Br J Cancer 1994; 69 (1): 101-103.
20. Winkler F, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell, 2004; 6 (6): 553-563.
21. Dolmans DE, Kadambi A, Hill JS, Flores KR, Gerber JN, Walker JP, Fukumura D,. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy. Cancer Res 2002; 62 (15): 4289-4294.
22. Boulikas T,. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol Rep 2004; 12 (1): 3-12.
23. Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK, Stathopoulos JG,. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: A phase I-II study. Oncol Rep 2006; 15 (5): 1201-1204.